Lymphatic and blood vessel morphometry in invasive breast carcinomas: Relation with proliferation and VEGF-C and -D proteins expression

Histology and Histopathology

Volumn 22, Issue 7-9, 2007, Pages 825-835

  Mylona, E ^a   Nomikos, A ^a   Alexandrou, P ^a   Giannopoulou, I ^a   Keramopoulos, A ^b   Nakopoulou, L ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiogenesis; Breast cancer; D2 40; Immunohistochemistry; Lymphangiogenesis; Morphometry; Proliferation

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING) A; PARAFFIN; VASCULOTROPIN C; VASCULOTROPIN D; CD34 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2 40; MONOCLONAL ANTIBODY D2-40; UNCLASSIFIED DRUG; VEGFC PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD VESSEL; BLOOD VESSEL DIAMETER; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CARCINOMA CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; COMPUTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EMBEDDING; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; SURVIVAL TIME; BREAST TUMOR; CANCER STAGING; CHEMISTRY; FEMALE; FOLLOW UP; IMMUNOLOGY; KAPLAN MEIER METHOD; METHODOLOGY; MICROCIRCULATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SIGNAL PROCESSING; TIME; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC VESSELS; MICROCIRCULATION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SIGNAL PROCESSING, COMPUTER-ASSISTED; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 34447133445     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K. and Stacker S.A. (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinase VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 95, 548-553.
2. Agarwal B., Saxena R., Morimiya A., Mehrotra S. and Badve S. (2005). Lymphangiogenesis does not occur in breast cancer. Am. J. Surg. Pathol. 29, 1449-1455.
3. Alitalo K. and Carmeliet P. (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227.
4. Axelsson K.,Ljung B.M., Moore D.H 2nd., Thor A.D., Chew K.L., Edgerton S.M., Smith H.S. and Mayall B. (1995). Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst. 87, 997-1008.
5. Bono P., Wasenius V-M., Heikkila P., Lundin J., Jackson D.G. and Joensuu H. (2004). High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin. Cancer Res. 10, 7144-7149.
6. Choi W.W., Lewis M.M., Lawson D., Yin-Goen Q., Birdsong G.G., Cotsonis G.A., Cohen C. and Young A.N. (2005). Angiogenic and lymphangiogenic microvessel denstiy in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod. Pathol. 18, 143-152.
7. Folkman J. (1997). Angiogenesis and angiogenesis inhibition: an overview. Experientia Suppl. 79, 1-8.
8. Franchi A., Gallo O., Mass! D., Baroni G. and Santucci M. (2004). Tumor lymphangiogenesis in head and neck squamous cell carcinoma. Cancer 101, 973-978.
9. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y., Saksela O., Kalkkinen N. and Alitalo K. (1997). Proteolytic processing regulates specificity and activity of VEGF-C. EMBO J. 16, 3898-3911.
10. Kahn H. and Marks A. (2002). A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab. Invest. 82, 1255-1257.
11. Leu A.J., Berk DA., Lymboussaki A., Alitalo K. and Jain R.K. (2000). Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Res. 60, 4324-4327.
12. Ludovini V., Sidoni A., Pistola L., Bellezza G., Bellezza G., De Angelis V., Gori S., Mosconi A.M., Bisagni G., Cherubini R., Bian A.R., Rodino C., Sabbatini R., Mazzochi B., Bucciarelli E., Tonato M. and Colozza M. (2000). Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res. Treat. 81, 159-168.
13. Medri L., Nanni O., Volpi A., Scarpi E., Dubin! A., Riccobon A., Becciolini A., Bianchi S. and Amadori D. (2000). Tumor microvessel density and prognosis in node-negative breast cancer. Int. J. Cancer 89, 74-80.
14. Nakamura Y., Yasuoka H., Tsujimoto M., Imabun S., Nakahara M., Nakao K., Nakamura M., Mori I. and Kakudo K. (2005). Lymph vessel density correlates with nodal status, VEGF-C expression and prognosis in breast cancer: Breast Cancer Res. Treat. 91, 125-132.
15. Nakopoulou L., Lazaris AC., Kavantzas N., Alexandrou P., Athanassiadou P., Keramopouios A. and Davaris P. (2000). DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 68, 137-143.
16. Ohta Y., Nozawa H., Tanaka Y., Oda M. and Watanabe Y. (2000). Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J. Thorac. Cardiovasc Surg. 119, 804-813.
17. Pepper M.S. (2001). Lymphangiogenesis and tumor metastasis: Myth or reality? Clinical Cancer Res. 7, 462-468.
18. Robins P., Pinder S. and de Klerk N. (1995). Histological grading of breast carcinomas: a study of interobserved agreement. Human Pathol. 28, 873-879.
19. Saharinen P., Tammela T., Karkkainen M.J. and Alitalo K. (1997). Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25, 387-395.
20. Schoppmann S.F., Bayer G., Aumayr K., Taucher S., Geleff S., Rudas M., Kubista E., Hausmaninger H., Samonigg H., Gnant M. and Jakes Z. (2004). Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann. Surg. 240, 306-312.
21. Stacker S.A., Caesar C., Baldwin M.E., Thomton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H and Achen M.G. (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186-190.
22. Stacker S.A., Baldwin M.E. and Achen M.G. (2002). The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 6, 922-934.
23. Tavassaoeli F.A. and Davilee P. (2003). Tumors of the breast and female genital organs IARC WHO. Classification of tumours No 4.
24. Tsutsui S., Kume M. and Era S. (2003). Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer 10, 312-319.
25. Union International Contre Cancer. (1992). TNM Classification of International Union against Cancer. In: TNM Atlas, 4th edn. 3rd revision. Hermanek P. and Sabin H. (eds). Springer-Verlag. Berlin.
26. Uzzan B., Nicolas P., Cucherat M. and Perret G-Y. (2004). Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res. 64, 2941-2955.
27. Veikkola T., Jussila L., Makinen T., Karpanen T., Jeltsch M., Petrova T.V., Kubo H., Thurston G., McDonald D.M., Achen M.G., Stacker S.A. and Alitalo K. (2001). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 223-1231.
28. Vleugel M.M., Bos R., van der Groep P., Greijer A.E., Shvarts A., Stel H.V., van der Wall E. and van Diest P.J. (2004). Lack of lymphangiogenesis during breast carcinogenesis. J. Clin. Pathol. 57, 746-751.
29. Weidner N., Semple J.P., Welch W.R. and Folkman J. (1991). Tumor angiogenesis and metastasis-carrelation in invasive breast carcinoma. New Engl. J. Med. 324, 1-8.
30. Williams C.S., Leek R.D., Robson A.M., Banerji S., Prevo, R., Harris A.L. and Jackson D.G. (2003). Absence of lymphangiogenesis and intratumoral lymph vessels in human metastatic breast cancer. J. Pathol. 200, 195-206.